Pipeline
A first-in-human, single ascending dose (SAD)/multiple ascending dose (MAD) study of AT-7687 is ongoing in the U.S.
AT-7687 is currently a once-weekly formulation, and the development of a monthly dose formulation is in progress.
Pioneering GIP
receptor antagonism for obesity treatment
We’re addressing obesity and overweight through GIP receptor antagonism, developing treatments that go beyond weight loss to deliver long-term sustained health, without compromising on tolerability.